These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30826660)

  • 1. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
    Kosumi K; Hamada T; Zhang S; Liu L; da Silva A; Koh H; Twombly TS; Mima K; Morikawa T; Song M; Nowak JA; Nishihara R; Saltz LB; Niedzwiecki D; Ou FS; Zemla T; Mayer RJ; Baba H; Ng K; Giannakis M; Zhang X; Wu K; Giovannucci EL; Chan AT; Fuchs CS; Meyerhardt JA; Ogino S
    Eur J Cancer; 2019 Apr; 111():82-93. PubMed ID: 30826660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.
    Mima K; Nishihara R; Yang J; Dou R; Masugi Y; Shi Y; da Silva A; Cao Y; Song M; Nowak J; Gu M; Li W; Morikawa T; Zhang X; Wu K; Baba H; Giovannucci EL; Meyerhardt JA; Chan AT; Fuchs CS; Qian ZR; Ogino S
    Clin Cancer Res; 2016 Aug; 22(15):3841-8. PubMed ID: 26957558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin use and risk of colorectal cancer according to BRAF mutation status.
    Nishihara R; Lochhead P; Kuchiba A; Jung S; Yamauchi M; Liao X; Imamura Y; Qian ZR; Morikawa T; Wang M; Spiegelman D; Cho E; Giovannucci E; Fuchs CS; Chan AT; Ogino S
    JAMA; 2013 Jun; 309(24):2563-71. PubMed ID: 23800934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
    Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S
    Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.
    Yamauchi M; Lochhead P; Imamura Y; Kuchiba A; Liao X; Qian ZR; Nishihara R; Morikawa T; Shima K; Wu K; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2013 Jun; 22(6):1142-52. PubMed ID: 23629521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
    Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour.
    Hamada T; Liu L; Nowak JA; Mima K; Cao Y; Ng K; Twombly TS; Song M; Jung S; Dou R; Masugi Y; Kosumi K; Shi Y; da Silva A; Gu M; Li W; Keum N; Wu K; Nosho K; Inamura K; Meyerhardt JA; Nevo D; Wang M; Giannakis M; Chan AT; Giovannucci EL; Fuchs CS; Nishihara R; Zhang X; Ogino S
    Eur J Cancer; 2018 Nov; 103():98-107. PubMed ID: 30219720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
    Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
    Haruki K; Kosumi K; Li P; Arima K; Väyrynen JP; Lau MC; Twombly TS; Hamada T; Glickman JN; Fujiyoshi K; Chen Y; Du C; Guo C; Väyrynen SA; Dias Costa A; Song M; Chan AT; Meyerhardt JA; Nishihara R; Fuchs CS; Liu L; Zhang X; Wu K; Giannakis M; Nowak JA; Ogino S
    Br J Cancer; 2020 Apr; 122(9):1367-1377. PubMed ID: 32157241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
    Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
    N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
    Hamada T; Cao Y; Qian ZR; Masugi Y; Nowak JA; Yang J; Song M; Mima K; Kosumi K; Liu L; Shi Y; da Silva A; Gu M; Li W; Keum N; Zhang X; Wu K; Meyerhardt JA; Giovannucci EL; Giannakis M; Rodig SJ; Freeman GJ; Nevo D; Wang M; Chan AT; Fuchs CS; Nishihara R; Ogino S
    J Clin Oncol; 2017 Jun; 35(16):1836-1844. PubMed ID: 28406723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
    Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
    Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Baba Y; Nosho K; Shima K; Goessling W; Chan AT; Ng K; Chan JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):822-31. PubMed ID: 20200425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
    Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
    Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
    Kim SA; Inamura K; Yamauchi M; Nishihara R; Mima K; Sukawa Y; Li T; Yasunari M; Morikawa T; Fitzgerald KC; Fuchs CS; Wu K; Chan AT; Zhang X; Ogino S; Qian ZR
    Br J Cancer; 2016 Jan; 114(2):199-206. PubMed ID: 26742007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
    Jun SY; Kim M; Jin Gu M; Kyung Bae Y; Chang HK; Sun Jung E; Jang KT; Kim J; Yu E; Woon Eom D; Hong SM
    Mod Pathol; 2016 Apr; 29(4):402-15. PubMed ID: 26892442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.